Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...
The Manila Times1h
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
SineuGene Therapeutics Co., Ltd. ('SineuGene'), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration ...
Clene Inc.: Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS tr ...
FMIBlog5h
Global Neurodegenerative Disease Market Poised for Remarkable Growth, Projected to Reach USD 102.4 Billion by 2034 at a CAGR of 7% | FMI
The global neurodegenerative disease market is on a trajectory of significant expansion, with its valuation expected to surge from USD 52.08 billion in 2024 to USD 102.4 billion by 2034, reflecting a ...
ALS News Today13m
MDA 2025: Cholesterol receptor ‘critical’ in sporadic ALS disease
A cholesterol receptor protein called LDLR appears to be a key driver of neurotoxicity in sporadic ALS, per new research ...